DexCom, Inc. logo

DexCom, Inc.

DXCM

NASDAQHealthcareMedical - Devices

最新資料

US$92.33

+US$2.12 · +2.35%

8月21日 下午3:55 ET

DXCM公司概覽

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

GoAI評分

Buy

Favorable setup — positive multi-factor alignment

估值

88

Deep Value

動能

56

Neutral

情緒

66

Bullish

風險韌性

60

Moderate Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考,並非投資建議。

公司概況

公司網站

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

產業
Medical - Devices
部門
Healthcare
總部
US
執行長
Jacob Steven Leach
上市以來
2005年4月14日
僱員
11,050

市場位置

成交量
348.18萬
0.62× 平均值
平均成交量
560.22萬
日均成交量
市值
348.46億 USD
貝塔
1.41
市場參考 1

財務數據

財務快照

最近十二個月

估值與收益率

本益比(TTM)
35.65×
股價淨值比(TTM)
13.52×
股價營收比(TTM)
7.01×
股息率
0.00%

獲利能力和效率

毛利率
62.47%
營業利益率
22.92%
淨利潤率
20.12%

財務健康

負債權益比
0.53×

DXCM同業公司

繼續GoAI的研究

在 GoAI 中研究DXCM

research.disclaimer